[go: up one dir, main page]

MX353827B - Formas de rifaximina y usos de la misma. - Google Patents

Formas de rifaximina y usos de la misma.

Info

Publication number
MX353827B
MX353827B MX2012009576A MX2012009576A MX353827B MX 353827 B MX353827 B MX 353827B MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 353827 B MX353827 B MX 353827B
Authority
MX
Mexico
Prior art keywords
rifaximin
forms
relates
present
therapeutic methods
Prior art date
Application number
MX2012009576A
Other languages
English (en)
Other versions
MX2012009576A (es
Inventor
S Gushurst Karen
Yang Donglai
Vlahova Petinka
S Stults Jeffrey
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2012009576A publication Critical patent/MX2012009576A/es
Publication of MX353827B publication Critical patent/MX353827B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a formas polimórficas de rifaximina, a su uso en preparaciones medicinales y a métodos terapéuticos que las utilizan.
MX2012009576A 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma. MX353827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof
PCT/US2011/024981 WO2011103120A1 (en) 2010-02-19 2011-02-16 Forms of rifaximin and uses thereof

Publications (2)

Publication Number Publication Date
MX2012009576A MX2012009576A (es) 2012-12-05
MX353827B true MX353827B (es) 2018-01-31

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009576A MX353827B (es) 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma.

Country Status (21)

Country Link
US (5) US8486956B2 (es)
EP (1) EP2536734B1 (es)
JP (2) JP2013520427A (es)
KR (1) KR20120140244A (es)
CN (2) CN102834398A (es)
AU (3) AU2011218258B2 (es)
BR (1) BR112012020863A2 (es)
CA (1) CA2790332A1 (es)
CR (1) CR20120449A (es)
EA (1) EA201270722A1 (es)
GE (2) GEP20156230B (es)
IL (1) IL221299A (es)
MA (1) MA34058B1 (es)
MX (1) MX353827B (es)
MY (1) MY158992A (es)
NZ (1) NZ601670A (es)
PH (1) PH12012501623A1 (es)
SG (1) SG183188A1 (es)
TN (1) TN2012000414A1 (es)
WO (1) WO2011103120A1 (es)
ZA (1) ZA201206227B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
JP5706693B2 (ja) 2008-02-25 2015-04-22 サリックス ファーマシューティカルズ リミテッド リファキシミンの型およびその使用
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CN102245615A (zh) 2008-10-02 2011-11-16 萨利克斯药品有限公司 治疗肝性脑病的方法
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US8513275B2 (en) * 2010-06-03 2013-08-20 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
JP5943915B2 (ja) * 2010-07-12 2016-07-05 サリックス ファーマスーティカルズ，リミテッド リファキシミンの製剤およびその使用
EP2616044A1 (en) * 2010-09-13 2013-07-24 Cilpa Limited Pharmaceutical composition
EA201391171A1 (ru) * 2011-02-11 2014-11-28 Сэликс Фармасьютиклз, Лтд. Формы рифаксимина и их применение
CA2834829A1 (en) * 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
JP2014532723A (ja) 2011-11-02 2014-12-08 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）及び感染症を治療するための方法
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CA2908525C (en) 2013-04-12 2021-04-06 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
EP3143027B1 (en) 2014-05-12 2019-07-10 Alfasigma S.p.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
US7226931B2 (en) * 2004-07-22 2007-06-05 Cumbre Pharmaceuticals Inc. (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
SI1698630T1 (sl) * 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2007298733B2 (en) 2006-09-22 2012-11-08 Cipla Limited Rifaximin
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
JP5706693B2 (ja) 2008-02-25 2015-04-22 サリックス ファーマシューティカルズ リミテッド リファキシミンの型およびその使用
PL2294012T3 (pl) * 2008-05-07 2014-12-31 Salix Pharmaceuticals Inc Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit
NZ592194A (en) 2008-09-17 2013-04-26 Mylan Inc Reversed wet granulation process for preparing granulates and pharmaceutical products containing them
EP2355805B1 (en) 2008-12-10 2019-02-13 Cipla Limited Rifaximin complexes
WO2011051971A2 (en) 2009-10-27 2011-05-05 Lupin Limited Solid dispersion of rifaximin
WO2011080691A1 (en) 2009-12-28 2011-07-07 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
US8513275B2 (en) * 2010-06-03 2013-08-20 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
EA201391171A1 (ru) * 2011-02-11 2014-11-28 Сэликс Фармасьютиклз, Лтд. Формы рифаксимина и их применение

Also Published As

Publication number Publication date
MY158992A (en) 2016-11-30
WO2011103120A1 (en) 2011-08-25
CA2790332A1 (en) 2011-08-25
TN2012000414A1 (en) 2014-01-30
AU2014246594A1 (en) 2014-10-30
AU2011218258A1 (en) 2012-08-30
CR20120449A (es) 2012-11-29
EA201270722A1 (ru) 2013-03-29
JP2013520427A (ja) 2013-06-06
KR20120140244A (ko) 2012-12-28
GEP20156230B (en) 2015-01-26
AU2016269529B2 (en) 2018-06-07
SG183188A1 (en) 2012-09-27
US20120316334A1 (en) 2012-12-13
AU2011218258B2 (en) 2015-11-05
IL221299A (en) 2017-11-30
US20140179916A1 (en) 2014-06-26
US8486956B2 (en) 2013-07-16
NZ601670A (en) 2014-11-28
ZA201206227B (en) 2018-12-19
US9034892B2 (en) 2015-05-19
US8569326B2 (en) 2013-10-29
CN102834398A (zh) 2012-12-19
CN105254647A (zh) 2016-01-20
MX2012009576A (es) 2012-12-05
BR112012020863A2 (pt) 2016-06-21
US9546183B2 (en) 2017-01-17
GEP201706745B (en) 2017-10-10
EP2536734A4 (en) 2013-06-26
AU2014246594B2 (en) 2016-09-15
MA34058B1 (fr) 2013-03-05
US9273066B2 (en) 2016-03-01
US20160200738A1 (en) 2016-07-14
US20100174064A1 (en) 2010-07-08
PH12012501623A1 (en) 2012-10-22
EP2536734A1 (en) 2012-12-26
IL221299A0 (en) 2012-10-31
EP2536734B1 (en) 2016-08-31
AU2016269529A1 (en) 2017-01-05
HK1179608A1 (zh) 2013-10-04
US20140141081A1 (en) 2014-05-22
JP2016094416A (ja) 2016-05-26

Similar Documents

Publication Publication Date Title
MX353827B (es) Formas de rifaximina y usos de la misma.
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
MX2015003140A (es) Formulaciones de enzalutamida.
MX2012013945A (es) Nuevas formas de rifaximina y usos de las mismas.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
SV2015004969A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
AR089993A1 (es) Macrociclos peptidomimeticos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX390891B (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
BR112013022883A2 (pt) aptâmero, composição farmacêutica, kit, uso de um aptâmero e coluna de aférese
UY34018A (es) Derivados glucósidos y usos de los mismos
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
MX347855B (es) Derivados de anilina, su preparación y su aplicación terapéutica.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”

Legal Events

Date Code Title Description
FG Grant or registration